PTC Study to Evaluate Ataluren in Combination With Ivacaftor
Condition: Cystic Fibrosis
MeSH terms: Cystic Fibrosis; Fibrosis
Intervention: Ataluren
Intervention description: ataluren
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 1.0
Sex: All
Minimum age: 6 Years
Healthy volunteers: No

Summary:

      The purpose of this study is to explore the combination of ataluren and ivacaftor as a
      treatment for patients with nonsense mutation cystic fibrosis
    

Eligibility criteria:

        Inclusion Criteria:

          1. Evidence of signed and dated informed consent/assent document(s) indicating that the
             subject (and/or his parent/legal guardian) has been informed of all pertinent aspects
             of the trial.

          2. Age ≥6 years

          3. Body weight ≥16 kg

          4. Diagnosis of cystic fibrosis and documentation of the presence of a nonsense mutations
             of the CFTR gene, as determined by historical genotyping

          5. Ability to perform a valid, reproducible spirometry with demonstration of a forced
             expiratory volume in 1second (FEV1) ≥30% and ≤90% of predicted for age, gender, and
             height.

          6. If the subject is sexually active, willingness to abstain from sexual intercourse or
             employ a barrier or medical method of contraception during the study drug
             administration

          7. Willingness and ability to comply with all study procedures and assessments.

          8. Currently being administered ivacaftor, either alone (Kalydeco) or in combination with
             lumacaftor (Orkambi)

        Exclusion Criteria:

          1. Any change (initiation, change in type of drug, dose modification, schedule
             modification, interruption, discontinuation, or re-initiation) in a chronic
             treatment/prophylaxis regimen for CF or for CF-related conditions within 2 weeks prior
             to screening.

          2. Ongoing participation in any other therapeutic clinical trial.

          3. Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection
             (including viral illnesses) within 2 weeks prior to screening.

          4. Ongoing inhaled tobramycin therapy.

          5. Ongoing immunosuppressive therapy (other than corticosteroids up to 10mg/d equivalent
             of prednisone)

          6. Ongoing warfarin, phenytoin, or tolbutamide therapy.

          7. History of solid organ or hematological transplantation.

          8. A history of positive hepatitis B surface antigen test, hepatitis C antibody test, or
             human immunodeficiency

          9. Major complications of lung disease (including massive hemoptysis, pneumothorax, or
             pleural effusion) within 4 weeks prior to screening.

         10. Pregnancy or breast-feeding.

         11. Current smoker or a smoking history of ≥10 pack-years (number of cigarette packs/day ×
             number of years smoked).

         12. Prior or ongoing medical condition (eg, renal failure, alcoholism, drug abuse,
             psychiatric condition), medical history, physical findings, ECG findings, or
             laboratory abnormality that, in the investigator's opinion, could adversely affect the
             safety of the subject, makes it unlikely that the course of treatment or follow-up
             would be completed, or could impair the assessment of study results.

             -